Black Diamond Therapeutics (BDTX) News Today $2.43 -0.12 (-4.71%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Down 13.5% in OctoberBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) saw a significant drop in short interest in October. As of October 31st, there was short interest totalling 6,330,000 shares, a drop of 13.5% from the October 15th total of 7,320,000 shares. Based on an average trading volume of 1,210,000 shares, the short-interest ratio is presently 5.2 days.November 16, 2024 | marketbeat.comFY2024 Earnings Estimate for BDTX Issued By HC WainwrightBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Investment analysts at HC Wainwright upped their FY2024 earnings estimates for shares of Black Diamond Therapeutics in a research note issued on Tuesday, November 5th. HC Wainwright analyst R. Burns now anticipates that the company wiNovember 8, 2024 | marketbeat.comWedbush Has Positive Outlook of BDTX FY2024 EarningsBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities researchers at Wedbush lifted their FY2024 EPS estimates for Black Diamond Therapeutics in a note issued to investors on Tuesday, November 5th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings perNovember 8, 2024 | marketbeat.comBlack Diamond Therapeutics Reports Promising Q3 2024 ResultsNovember 7, 2024 | markets.businessinsider.comBlack Diamond Therapeutics (NASDAQ:BDTX) Receives "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday.November 6, 2024 | marketbeat.comStrong Buy Rating for Black Diamond Therapeutics Driven by Financial Stability and Promising Clinical DevelopmentsNovember 5, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Financial Stability Support Buy Rating for Black Diamond TherapeuticsNovember 5, 2024 | markets.businessinsider.comBlack Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 5, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in Upcoming Investor ConferencesNovember 1, 2024 | globenewswire.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest UpdateBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totalling 7,320,000 shares, an increase of 5.9% from the September 30th total of 6,910,000 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is presently 6.2 days.October 31, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Growth in Short InterestBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 6,910,000 shares, a growth of 17.9% from the September 15th total of 5,860,000 shares. Based on an average daily volume of 1,120,000 shares, the days-to-cover ratio is currently 6.2 days.October 14, 2024 | marketbeat.comFY2024 EPS Estimates for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Increased by AnalystBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Stock analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for Black Diamond Therapeutics in a research note issued on Wednesday, October 9th. HC Wainwright analyst R. Burns now anticipates that the companyOctober 11, 2024 | marketbeat.comWedbush Comments on Black Diamond Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:BDTX)Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Equities research analysts at Wedbush dropped their Q3 2024 EPS estimates for shares of Black Diamond Therapeutics in a report issued on Monday, October 7th. Wedbush analyst R. Driscoll now forecasts that the company will post earningOctober 10, 2024 | marketbeat.comBlack Diamond Therapeutic (NASDAQ:BDTX) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comTD Cowen Keeps Their Buy Rating on Black Diamond Therapeutics (BDTX)October 9, 2024 | markets.businessinsider.comBlack Diamond Therapeutics (BDTX) Receives a Buy from WedbushOctober 9, 2024 | markets.businessinsider.comBlack Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 DataOctober 9, 2024 | seekingalpha.comBlack Diamond Therapeutics to Cut Jobs Amid Restructuring, Names New CFOOctober 8, 2024 | marketwatch.comBlack Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash RunwayOctober 7, 2024 | globenewswire.comAffinity Asset Advisors LLC Invests $3.03 Million in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Affinity Asset Advisors LLC acquired a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) during the second quarter, according to its most recent filing with the SEC. The fund acquired 650,000 shares of the company's stock, valued at approximately $3,029,000. AffiniSeptember 25, 2024 | marketbeat.comBuy Rating on Black Diamond Therapeutics: Promising Phase 2 Results for BDTX-1535 in NSCLC TreatmentSeptember 25, 2024 | markets.businessinsider.comBlack Diamond Therapeutics (NASDAQ:BDTX) PT Raised to $15.00 at Piper SandlerPiper Sandler lifted their price objective on Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an "overweight" rating in a report on Monday.September 23, 2024 | marketbeat.comBlack Diamond Therapeutics Shares Jump on Positive Data for Cancer TreatmentSeptember 23, 2024 | marketwatch.comBlack Diamond Therapeutics Gains On Positive Phase 2 Data For BDTX-1535 In Patients With NSCLCSeptember 23, 2024 | markets.businessinsider.comBlack Diamond reports encouraging Phase 2 data for BDTX-1535September 23, 2024 | msn.comAlly Bridge Group NY LLC Makes New Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Ally Bridge Group NY LLC acquired a new position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 835,000 shares of the company's stock, valueSeptember 23, 2024 | marketbeat.comBlack Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance MutationsSeptember 23, 2024 | globenewswire.comBlack Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLCSeptember 22, 2024 | globenewswire.comBuy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment AdvancesSeptember 19, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Black Diamond Therapeutics (BDTX)September 16, 2024 | markets.businessinsider.comTD Asset Management Inc Purchases 195,464 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)TD Asset Management Inc boosted its holdings in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 275.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 266,312 shares of the company's stock afterSeptember 15, 2024 | marketbeat.comBlack Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024September 14, 2024 | globenewswire.comWedbush Reaffirms Their Buy Rating on Black Diamond Therapeutics (BDTX)September 11, 2024 | markets.businessinsider.comBlack Diamond Therapeutics (BDTX) Gets a Buy from Piper SandlerSeptember 11, 2024 | markets.businessinsider.comBlack Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Reaffirmed by WedbushWedbush reissued an "outperform" rating and issued a $16.00 target price on shares of Black Diamond Therapeutics in a report on Tuesday.September 10, 2024 | marketbeat.comQ3 2024 Earnings Estimate for Black Diamond Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:BDTX)Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Analysts at HC Wainwright upped their Q3 2024 earnings estimates for Black Diamond Therapeutics in a report released on Wednesday, September 4th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($September 6, 2024 | marketbeat.comBuy Rating Reaffirmed for Black Diamond Therapeutics Amid Promising Clinical Trials and Solid FinancialsSeptember 5, 2024 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Black Diamond Therapeutics (NASDAQ:BDTX)HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday.September 4, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Significant Increase in Short InterestBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the recipient of a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 6,010,000 shares, an increase of 35.4% from the July 31st total of 4,440,000 shares. Based on an average daily volume of 637,100 shares, the days-to-cover ratio is presently 9.4 days.August 29, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Down 6.1% in JulyBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 4,440,000 shares, a decline of 6.1% from the July 15th total of 4,730,000 shares. Based on an average trading volume of 689,200 shares, the short-interest ratio is currently 6.4 days.August 19, 2024 | marketbeat.comBuy Rating on Black Diamond Therapeutics: Promising Early Results for BDTX-1535 in NSCLC TreatmentAugust 6, 2024 | markets.businessinsider.comBlack Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 6, 2024 | globenewswire.comBlack Diamond Therapeutics (NASDAQ:BDTX) Now Covered by Analysts at Raymond JamesRaymond James started coverage on shares of Black Diamond Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $20.00 price target on the stock.July 31, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Significant Growth in Short InterestBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) saw a large growth in short interest in July. As of July 15th, there was short interest totalling 4,730,000 shares, a growth of 47.4% from the June 30th total of 3,210,000 shares. Based on an average daily volume of 760,200 shares, the short-interest ratio is currently 6.2 days.July 27, 2024 | marketbeat.comBlack Diamond Therapeutics' (BDTX) "Overweight" Rating Reiterated at Piper SandlerPiper Sandler reissued an "overweight" rating and issued a $12.00 target price on shares of Black Diamond Therapeutics in a research note on Wednesday.July 3, 2024 | marketbeat.comBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Up 22.4% in MayBlack Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 2,620,000 shares, a growth of 22.4% from the May 15th total of 2,140,000 shares. Based on an average daily trading volume, of 670,800 shares, the days-to-cover ratio is presently 3.9 days.June 15, 2024 | marketbeat.comBellevue Group AG Has $23.99 Million Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)Bellevue Group AG grew its holdings in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) by 4.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,535,839 shares of the company's stock after buying an addiJune 10, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Black Diamond Therapeutics (NASDAQ:BDTX)HC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a report on Friday.June 7, 2024 | marketbeat.comBlack Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingJune 1, 2024 | globenewswire.comBlack Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceMay 29, 2024 | globenewswire.com Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO BDTX Media Mentions By Week BDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDTX News Sentiment▼1.920.46▲Average Medical News Sentiment BDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDTX Articles This Week▼11▲BDTX Articles Average Week Get Black Diamond Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BDTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CGEN News Today INBX News Today ITOS News Today CCCC News Today ALEC News Today CDXC News Today IGMS News Today ABVX News Today HUMA News Today ATXS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Black Diamond Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Black Diamond Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
